REG - Poolbeg Pharma PLC - POLB 001 CRS patent granted in Canada

Poolbeg PharmaAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260511:nRSK6778Da&default-theme=true

RNS Number : 6778D  Poolbeg Pharma PLC  11 May 2026

 

Poolbeg Pharma plc

 

POLB 001 cancer immunotherapy-induced CRS patent granted in Canada

 

Further strengthening of Poolbeg's global intellectual property portfolio

 

11 May 2026 - Poolbeg Pharma
(https://protect.checkpoint.com/v2/r02/___https:/www.poolbegpharma.com/___.YXAxZTpzaG9yZWNhcDpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDphNDZlOGM3N2U4MzVjYmEwZjU2ZjJkZTAzYjQ2M2RhMzo3OmVkNWU6YmVhNDdjMWVlOTQ1YTNiMjY4MTBmYmZhNjE3NDJjMjUxNGMzNDkzZmVkMzRlYmI3MjUxODZlNDY2ZjY2YmIzZjpwOkY6Tg)
 (AIM: POLB, 'Poolbeg' or the 'Company'), a clinical-stage biopharmaceutical
company with a core focus on transforming the cancer immunotherapy field,
announces that it has received formal notification of the grant for its POLB
001 cancer immunotherapy-induced Cytokine Release Syndrome ("CRS") patent
application from the Canadian patent office.

 

This represents the second national grant within Poolbeg's cancer
immunotherapy-induced CRS patent family, following the grant by IP Australia
announced in March 2026, and marks a further important milestone for the
Company. This patent covers the use of any p38 MAPK inhibitor, including POLB
001, for the prevention of cancer immunotherapy-induced CRS, and is
underpinned by proprietary data generated by Poolbeg.

 

Poolbeg filed its initial oncology patent applications in the UK in January
2023 before entering the international Patent Cooperation Treaty system in
January 2024. This new patent grant was accelerated through the Patent
Prosecution Highway, which enables expedited examination in participating
countries where a favourable ruling has already been secured in another
participating jurisdiction.

 

The Company's IP portfolio now spans both cancer immunotherapy-induced CRS and
severe influenza across multiple jurisdictions, and Poolbeg continues to
pursue protection in further territories. This grant further strengthens the
Company's robust intellectual property portfolio, enhancing POLB 001's future
value and appeal to potential partners.

 

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, said:
"This Canadian patent grant, coming shortly after our first oncology patent
grant in Australia, further strengthens our IP position for POLB 001 and
demonstrates the momentum we have built in expanding this patent family
globally. With interim data from the TOPICAL trial expected this summer, we
believe this patent grant further enhances the attractiveness of POLB 001 to
prospective partners. We will continue to pursue coverage in other
jurisdictions and look forward to updating shareholders on our progress."

 

*TOPICAL: Trial of Prevention of ImmunoCytokine Adverse events in Myeloma. A
single-arm, open-label trial investigating POLB 001 as a potential
preventative for CRS in relapsed/refractory multiple myeloma patients
receiving the approved bispecific antibody, teclistamab, provided by Johnson
and Johnson at no cost to Poolbeg.

 

 

Enquiries

 

 Poolbeg Pharma Plc                                            +44 (0) 207 183 1499

 Jeremy Skillington, CEO                                       ir@poolbegpharma.com (mailto:ir@poolbegpharma.com)

 Ian O'Connell, CFO

  
 Cavendish Capital Markets Ltd (NOMAD & Joint Broker)          +44 (0) 207 220 0500

 Geoff Nash, Trisyia Jamaludin (Corporate Finance)

 Nigel Birks (Life Science Specialist Sales)

 Harriet Ward (ECM)

  
 Shore Capital Stockbrokers Ltd (Joint Broker)                 +44 (0) 207 408 4090

 David Coaten, Harry Davies-Ball (Corporate Advisory)

Malachy McEntyre (Corporate Broking)
 J&E Davy (Joint Broker)                                       +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

  
 Optimum Strategic Communications                              +44 (0) 208 078 4357

 Nick Bastin, Katie Flint, Elena Bates                         poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

  

 

About Poolbeg Pharma plc

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage
biopharmaceutical company with a core focus on transforming the cancer
immunotherapy field. The Company's lead asset, POLB 001, has the potential to
expand administration of cancer immunotherapies from centralised specialist
cancer centres into community hospitals by making the treatments safer through
the prevention of the life-threatening side effect, Cytokine Release Syndrome
(CRS). As such, POLB 001 could increase the number of patients that can
receive these life-saving treatments, thereby increasing the market
opportunity. Poolbeg is also advancing the development of a patient-friendly
therapy for obesity with an oral encapsulated GLP-1, offering a differentiated
approach within one of the world's largest markets. With multiple near-term
clinical value inflection points, and an experienced team with a proven track
record, Poolbeg is focussed on partnering its high value programmes that are
targeting large markets and addressing critical unmet medical needs.

 

Stay updated: Website
(https://protect.checkpoint.com/v2/r02/___http:/www.poolbegpharma.com___.YXAxZTpzaG9yZWNhcDpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDphNDZlOGM3N2U4MzVjYmEwZjU2ZjJkZTAzYjQ2M2RhMzo3OjRlNmI6MGY2ZDJhNDNlOWVjNzllZGZlMGQ4M2E5MTk4MDFiMzhjNDZiMzk2M2E5OGJkMTVmZGJhYmVhODUwZTk3YzgzZTpwOkY6Tg)
| Sign up for RNS alerts
(https://protect.checkpoint.com/v2/r02/___https:/www.poolbegpharma.com/investors/regulatory-news-email-alerts/___.YXAxZTpzaG9yZWNhcDpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDphNDZlOGM3N2U4MzVjYmEwZjU2ZjJkZTAzYjQ2M2RhMzo3OmFlMDE6NjA1ZDFjMDNlM2E5YTVlYjM5MjJkNGZkMWE0NTllZTlmMDczMzQ2Y2U2YzcyYWQ4NTk3MGEyNzM1YzExMDYzMzpwOkY6Tg#email-alerts)
| Presentation
(https://protect.checkpoint.com/v2/r02/___https:/www.poolbegpharma.com/investors/events-presentations/___.YXAxZTpzaG9yZWNhcDpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDphNDZlOGM3N2U4MzVjYmEwZjU2ZjJkZTAzYjQ2M2RhMzo3OjVmNzI6OTk4Mzg3MGNmNTFiZjFjNjcyMWU3OTI0ODVlMjhmMDkzN2ZlY2ExMDI4NGY4ZTJhNDU3Njk4YmE3ODE3ZGY1MTpwOkY6Tg)
 | X
(https://protect.checkpoint.com/v2/r02/___https:/x.com/PoolbegPharma___.YXAxZTpzaG9yZWNhcDpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDphNDZlOGM3N2U4MzVjYmEwZjU2ZjJkZTAzYjQ2M2RhMzo3OmE1NzQ6MTA1MjlkYjYzZjQwNTVmMTZlZjEwZjdlZmE2ZDc4ZTcxZWI0YjhlOTU2MzA2ZWNiMzcyYzkyYmM2MDFjZTVkNzpwOkY6Tg)
 | LinkedIn
(https://protect.checkpoint.com/v2/r02/___https:/www.linkedin.com/company/poolbeg-pharma/___.YXAxZTpzaG9yZWNhcDpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDphNDZlOGM3N2U4MzVjYmEwZjU2ZjJkZTAzYjQ2M2RhMzo3OjU3ODQ6NDdiMGNiNTMyNGQ0MzJlOTJhN2EyNDU1YmJmMWJiNzZlZjhiNGFlMWYzNGE4Mzc5OTQwOWZmYmZmYTVhOGVlMjpwOkY6Tg)

 

Forward-Looking Statements

This announcement may contain forward-looking statements and the words
"expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast",
"project" and similar expressions (or their negative) identify certain of
these forward-looking statements. The forward-looking statements in this
announcement are based on numerous assumptions and Poolbeg's present and
future business strategies and the environment in which Poolbeg expects to
operate in the future. Forward-looking statements involve inherent known and
unknown risks, uncertainties and contingencies because they relate to events
and depend on circumstances that may or may not occur in the future and may
cause the actual results, performance or achievements to be materially
different from those expressed or implied by such forward-looking statements.
These statements are not guarantees of future performance or the ability to
identify and consummate investments. Many of these risks and uncertainties
relate to factors that are beyond Poolbeg's ability to control or estimate
precisely, such as future market conditions, currency fluctuations, the
behaviour of other market participants, the outcome of clinical trials, the
actions of regulators and other factors such as Poolbeg's ability to obtain
financing, changes in the political, social and regulatory framework in which
Poolbeg operates or in economic, technological or consumer trends or
conditions. Past performance should not be taken as an indication or guarantee
of future results, and no representation or warranty, express or implied, is
made regarding future performance. No person is under any obligation to update
or keep current the information contained in this announcement or to provide
the recipient of it with access to any additional relevant information.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDVLFBQELBBBF



            Copyright 2019 Regulatory News Service, all rights reserved